stockrowVir Biotechnology, Inc.
VIRVir Biotechnology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $68.6 million, down 7.61% from fiscal 2024.
- Revenue
- −178.3%
- EPS
- +51.4%
- Free cash flow
- +36.8%
Quarter to September 2026, against a year earlier
Follow VIR
Alert me
Vir Biotechnology, Inc. (VIR) Return on equity
Vir Biotechnology, Inc.'s return on equity over the twelve months to 30 September 2026 was −21.8%, up 23.9 percentage points from fiscal 2025 (−45.7%). Over the past ten years it has ranged from −142.7% (fiscal 2019) to 93.4% (fiscal 2018); the current reading is higher than 33% of that period. That is above the Biotechnology industry median of −50.3% and above the Healthcare sector median of −25.6%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −45.7% | (7.64) |
| FY2024 | −38.1% | (4.56) |
| FY2023 | −33.5% | (62.92) |
| FY2022 | 29.4% | (19.81) |
| FY2021 | 49.2% | 101.56 |
| FY2020 | −52.4% | 90.38 |
| FY2019 | −142.7% | (236.13) |
| FY2018 | 93.4% | 37.06 |
| FY2017 | 56.3% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| BHVN Biohaven Ltd. compare | 940.5% |
| ZYME Zymeworks Inc. compare | 15.0% |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 0.00% |
| TRAX First Tracks Biotherapeutics, Inc. compare | 0.00% |
| VIR Vir Biotechnology, Inc. | −21.8% |
| NAMS NewAmsterdam Pharma Company N.V. compare | −30.2% |
| RXRX Recursion Pharmaceuticals, Inc. compare | −48.7% |
| IMNM Immunome, Inc. compare | −78.7% |
| REPL Replimune Group, Inc. compare | −115.8% |
| Biotechnology industry median | −50.3% |
| Healthcare sector median | −25.6% |
| Market median | 1.95% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on VIR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement